Top

Published in:

Open Access 01-04-2020 | Atrial Fibrillation | Original Paper

Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation

Authors: Paweł T. Matusik, Barbara Małecka, Jacek Lelakowski, Anetta Undas

Published in: Clinical Research in Cardiology | Issue 4/2020

Abstract

We investigated whether growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-1), levels are associated with a prothrombotic state in atrial fibrillation (AF) as compared to N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI-hs). In 103 patients with AF assessed off anticoagulation (age: 71.0 [65.0–76.0] years; CHA₂DS₂-VASc score: 4.6 ± 1.7), we measured endogenous thrombin potential (ETP), plasma fibrin clot permeability (K_s, a measure of clot density) and clot lysis time (CLT) and other hemostatic parameters, along with GDF-15, NT-proBNP, and cTnI-hs. GDF-15 positively correlated with ETP and CLT (r = 0.25, P = 0.01 and R = 0.56, P < 0.0001, respectively) but not with K_s, von Willebrand factor, thrombin-activatable fibrinolysis inhibitor, plasminogen, antiplasmin or tissue-type plasminogen activator antigen. NT-proBNP showed a stronger association with ETP (r = 0.60, P < 0.0001) and a similar correlation with CLT (R = 0.53, P < 0.0001), while cTnI-hs correlated solely with CLT (R = 0.25, P = 0.01). After adjustment for clinical and laboratory parameters, GDF-15 was a better independent predictor of CLT (unstandardized coefficient B 0.009; 95% confidence interval [CI] 0.006–0.012) than NT-proBNP (B 0.007; 95% CI 0.004–0.010, R (2) = 0.51; P < 0.0001); while among the three biomarkers, only NT-proBNP was an independent predictor of ETP. Elevated GDF-15 and NT-proBNP independently predict impaired fibrin clot lysability, while NT-proBNP is a key predictor of heightened thrombin formation in AF. Our findings suggest that a predictive value of NT-proBNP and GDF-15 in AF could be in part attributed to their association with prothrombotic blood alterations.

Graphic Abstract

Available only for authorised users

Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, Hernandez-Romero D, Valdes M, Vicente V, Lip GY, Marin F (2017) Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep 7:41565. https://doi.org/10.1038/srep41565 CrossRefPubMedPubMedCentral

Glowicki B, Matusik PT, Plens K, Undas A (2019) Prothrombotic state in atrial fibrillation patients with one additional risk factor of the CHA2DS2-VASc score (beyond sex). Can J Cardiol 35(5):634–643. https://doi.org/10.1016/j.cjca.2019.01.014 CrossRefPubMed

Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L, RE-LY and ARISTOTLE Investigators, Investigators A (2016) Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation 134(22):1697–1707. https://doi.org/10.1161/CIRCULATIONAHA.116.022802 CrossRefPubMed

Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L, ARISTOTLE and STABILITY Investigators (2016) The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 37(20):1582–1590. https://doi.org/10.1093/eurheartj/ehw054 CrossRefPubMedPubMedCentral

Matusik PT, Matusik PS, Kornacewicz-Jach Z, Malecka B, Zabek A, Undas A (2017) Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. Int J Cardiol 243:244–250. https://doi.org/10.1016/j.ijcard.2017.05.060 CrossRefPubMed

Matusik PT, Prior SM, Butenas S, Malecka B, Lelakowski J, Undas A (2018) Association of cardiac troponin I with prothrombotic alterations in atrial fibrillation. Kardiol Pol 76(7):1106–1109. https://doi.org/10.5603/KP.2018.0134 CrossRefPubMed

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA (2019) Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 139(6):760–771. https://doi.org/10.1161/CIRCULATIONAHA.118.038312 CrossRefPubMedPubMedCentral

Matusik PT (2019) Biomarkers and cardiovascular risk stratification. Eur Heart J 40(19):1483–1485. https://doi.org/10.1093/eurheartj/ehz265 CrossRefPubMed

Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L, Investigators R-L Aristotle (2018) A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J 39(6):477–485. https://doi.org/10.1093/eurheartj/ehx584 CrossRefPubMed

10.

Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, ARISTOTLE Investigators (2014) Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130(21):1847–1858. https://doi.org/10.1161/CIRCULATIONAHA.114.011204 CrossRefPubMed

11.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L (2017) Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Am Heart J 190:94–103. https://doi.org/10.1016/j.ahj.2017.06.001 CrossRefPubMed

12.

Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L, ARISTOTLE and RE-LY Investigators (2016) The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 387(10035):2302–2311. https://doi.org/10.1016/S0140-6736(16)00741-8 CrossRefPubMed

13.

Hu XF, Zhan R, Xu S, Wang J, Wu J, Liu X, Li Y, Chen L (2018) Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Clin Cardiol 41(1):34–38. https://doi.org/10.1002/clc.22844 CrossRefPubMedPubMedCentral

14.

Hemker HC, Al Dieri R, De Smedt E, Beguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96(5):553–561PubMed

15.

Hemker HC, Kremers R (2013) Data management in thrombin generation. Thromb Res 131(1):3–11. https://doi.org/10.1016/j.thromres.2012.10.011 CrossRefPubMed

16.

Siudut J, Grela M, Wypasek E, Plens K, Undas A (2016) Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost 14(4):784–793. https://doi.org/10.1111/jth.13264 CrossRefPubMed

17.

Meus R, Son M, Sobczyk D, Undas A (2016) Prothrombotic state in patients with a left atrial appendage thrombus of unknown origin and cerebrovascular events. Stroke 47(7):1872–1878. https://doi.org/10.1161/STROKEAHA.116.012856 CrossRefPubMed

18.

Bewick V, Cheek L, Ball J (2004) Statistics review 8: qualitative data—tests of association. Crit Care 8(1):46–53. https://doi.org/10.1186/cc2428 CrossRefPubMed

19.

Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94(21):11514–11519. https://doi.org/10.1073/pnas.94.21.11514 CrossRefPubMed

20.

Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM (2019) Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci 56(5):333–350. https://doi.org/10.1080/10408363.2019.1615034 CrossRefPubMed

21.

Rossaint J, Vestweber D, Zarbock A (2013) GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost 11(2):335–344. https://doi.org/10.1111/jth.12100 CrossRefPubMed

22.

Eggers KM, Kempf T, Lind L, Sundstrom J, Wallentin L, Wollert KC, Siegbahn A (2012) Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 72(1):45–51. https://doi.org/10.3109/00365513.2011.626072 CrossRefPubMed

23.

Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA, Storey RF (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J 39(13):1078–1085. https://doi.org/10.1093/eurheartj/ehy013 CrossRefPubMedPubMedCentral

24.

Violi F, Pastori D, Pignatelli P, Loffredo L (2014) Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. Europace 16(8):1107–1116. https://doi.org/10.1093/europace/euu040 CrossRefPubMed

25.

Pignatelli P, Menichelli D, Pastori D, Violi F (2018) Oxidative stress and cardiovascular disease: new insights. Kardiol Pol 76(4):713–722. https://doi.org/10.5603/KP.a2018.0071 CrossRefPubMed

26.

Drabik L, Wolkow P, Undas A (2017) Fibrin clot permeability as a predictor of stroke and bleeding in anticoagulated patients with atrial fibrillation. Stroke 48(10):2716–2722. https://doi.org/10.1161/STROKEAHA.117.018143 CrossRefPubMed

27.

Janion-Sadowska A, Chrapek M, Konieczynska M, Undas A (2018) Altered fibrin clot properties predict stroke and bleedings in patients with atrial fibrillation on rivaroxaban. Stroke 50(1):185–188. https://doi.org/10.1161/STROKEAHA.118.023712 CrossRef

28.

Thomas D, Christ T, Fabritz L, Goette A, Hammwohner M, Heijman J, Kockskamper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N (2019) German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. Clin Res Cardiol 108(6):577–599. https://doi.org/10.1007/s00392-018-1377-1 CrossRefPubMed

29.

Litwinowicz R, Bartus M, Ceranowicz P, Kapelak B, Lakkireddy D, Bartus K (2018) Stroke risk reduction after left atrial appendage occlusion in elderly patients with atrial fibrillation: long-term results. Pol Arch Intern Med 128(5):327–329. https://doi.org/10.20452/pamw.4264 CrossRefPubMed

30.

Feyz L, Theuns DA, Bhagwandien R, Strachinaru M, Kardys I, Van Mieghem NM, Daemen J (2019) Atrial fibrillation reduction by renal sympathetic denervation: 12 months’ results of the AFFORD study. Clin Res Cardiol 108(6):634–642. https://doi.org/10.1007/s00392-018-1391-3 CrossRefPubMed

31.

Semmler V, von Krogh F, Haller B, Reents T, Bourier F, Telishevska M, Kottmaier M, Kornmayer M, Brooks S, Koch-Buttner K, Lennerz C, Brkic A, Grebmer C, Blazek P, Weigand S, Hessling G, Kolb C, Deisenhofer I (2019) The incidence, indications and predictors of acute pacemaker implantation after ablation of persistent atrial fibrillation. Clin Res Cardiol 108(6):651–659. https://doi.org/10.1007/s00392-018-1393-1 CrossRefPubMed

32.

Maurer T, Rottner L, Makimoto H, Reissmann B, Heeger CH, Lemes C, Fink T, Riedl J, Santoro F, Wohlmuth P, Volkmer M, Mathew S, Metzner A, Ouyang F, Kuck KH, Sohns C (2018) The best of two worlds? Pulmonary vein isolation using a novel radiofrequency ablation catheter incorporating contact force sensing technology and 56-hole porous tip irrigation. Clin Res Cardiol 107(11):1003–1012. https://doi.org/10.1007/s00392-018-1270-y CrossRefPubMed

33.

Matusik PT, Tomala I, Piekarz J, Karkowski G, Kuniewicz M, Lelakowski J (2016) Thyroid goiter: implications for implantation of cardiovascular implantable electronic devices and cannulation of the superior vena cava confluence. Pol Arch Med Wewn 126(6):432–434. https://doi.org/10.20452/pamw.3459 CrossRefPubMed

34.

de Jong MR, Hoogerwaard AF, Adiyaman A, Smit JJJ, Ramdat Misier AR, Heeg JE, van Hasselt B, Van Gelder IC, Crijns H, Lozano IF, Toquero Ramos JE, Javier Alzueta F, Ibanez B, Rubio JM, Arribas F, Porres Aracama JM, Brugada J, Mont L, Elvan A (2018) Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : the ASAF trial: ablation of sympathetic atrial fibrillation. Clin Res Cardiol 107(7):539–547. https://doi.org/10.1007/s00392-018-1214-6 CrossRefPubMed

35.

Buist TJ, Adiyaman A, Smit JJJ, Ramdat Misier AR, Elvan A (2018) Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation. Clin Res Cardiol 107(6):498–506. https://doi.org/10.1007/s00392-018-1211-9 CrossRefPubMed

36.

Sohns C, Metzner A, Chmelevsky M, Kuck KH (2018) A new algorithm to visualize the individual relationship between electrical rotors from non-invasive panoramic mapping and atrial fibrosis to guide ablation of persistent atrial fibrillation. Clin Res Cardiol 107(5):444–446. https://doi.org/10.1007/s00392-017-1196-9 CrossRefPubMed

37.

Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA (2018) Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J 39(43):3867–3875. https://doi.org/10.1093/eurheartj/ehy421 CrossRefPubMed

38.

Zabczyk M, Undas A (2017) Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med 127(12):873–881. https://doi.org/10.20452/pamw.4165 CrossRefPubMed

39.

Undas A, Zabczyk M (2018) Antithrombotic medications and their impact on fibrin clot structure and function. J Physiol Pharmacol. https://doi.org/10.26402/jpp.2018.4.02 CrossRefPubMed

Title: Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation
Authors: Paweł T. Matusik
Barbara Małecka
Jacek Lelakowski
Anetta Undas
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keywords: Atrial Fibrillation
Biomarkers
Published in: Clinical Research in Cardiology / Issue 4/2020
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-019-01522-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation

Abstract

Graphic Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphic Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system

Publisher Correction to: Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction

Ludger Seipel: an early comer in clinical electrophysiology at 80 years

Response letter to Shetty and Shetty’s reply about DRAIN trial

Management and outcomes of patients with unstable angina with undetectable, normal, or intermediate hsTnT levels

A reply to “Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure—bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial”

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page